Education
About Us
Working with TipRanks
Follow Us
Restart Life Sciences (NMLSF)
OTHER OTC:NMLSF
NMLSF Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.02 - $0.15
Previous CloseN/A
Volume8.00K
Average Volume (3M)5.18K
Market Cap
$1.20M
Enterprise Value$994.70K
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)0.00
Price to Earnings (P/E)4.2
Beta3.07
Next Earnings
Jun 03, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.01
Shares Outstanding33,230,354
10 Day Avg. Volume5,322
30 Day Avg. Volume5,184
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
Restart Life Sciences News
PremiumCompany Announcements
Nova Mentis Announces Share Consolidation and Name ChangePremiumCompany Announcements
Nova Mentis Appoints New CEO to Drive Growth
PremiumCompany Announcements
Nova Mentis Life Science Announces Strategic IP Deal
PremiumCompany Announcements
Nova Mentis Welcomes New Board Member---
Options Prices
Currently, No data available
---
Ownership Overview
NMLSF FAQ
What was Restart Life Sciences’s price range in the past 12 months?
Restart Life Sciences lowest stock price was $0.02 and its highest was $0.15 in the past 12 months.
What is Restart Life Sciences’s market cap?
Restart Life Sciences’s market cap is $1.20M.
When is Restart Life Sciences’s upcoming earnings report date?
Restart Life Sciences’s upcoming earnings report date is Jun 03, 2025 which is in 33 days.
How were Restart Life Sciences’s earnings last quarter?
Restart Life Sciences released its earnings results on Apr 08, 2025. The company reported $0 earnings per share for the quarter, the consensus estimate of N/A by $0.
Is Restart Life Sciences overvalued?
According to Wall Street analysts Restart Life Sciences’s price is currently Overvalued.
Does Restart Life Sciences pay dividends?
Restart Life Sciences does not currently pay dividends.
What is Restart Life Sciences’s EPS estimate?
Restart Life Sciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Restart Life Sciences have?
Restart Life Sciences has 33,230,354 shares outstanding.
What happened to Restart Life Sciences’s price movement after its last earnings report?
Restart Life Sciences reported an EPS of $0 in its last earnings report, expectations of N/A. Following the earnings report the stock price went up 100%.
Which hedge fund is a major shareholder of Restart Life Sciences?
Currently, no hedge funds are holding shares in NMLSF
---
Company Description
Restart Life Sciences
Nova Mentis Life Science Corp., through its subsidiaries, engages in developing diagnostics and psilocybin based therapeutics for neuroinflammatory conditions with a focus on autism spectrum disorder and fragile X syndrome in Canada. It is also involved in the research and development of anti-inflammatory effects of psilocybin for metabolic indications, such as obesity and diabetes; and development of cannabis products. Nova Mentis Life Science Corp. has a research agreement with the University of Central Florida (UCF) to develop a saliva serotonin assay. The company was formerly known as Liberty Leaf Holdings Ltd. and changed its name to Nova Mentis Life Science Corp. in June 2020. Nova Mentis Life Science Corp. was incorporated in 2004 and is headquartered in Vancouver, Canada.
---
Technical Analysis
---